Showing results (1-10 of 166) with videos related to
Sort By:
Pageof 17
Expert Review of Neurotherapeutics|August 26, 2011
What happens when natalizumab therapy is stopped?Stephen M Schaaf, David Pitt, Michael K RackeAnnals of Indian Academy of Neurology|February 26, 2010
Immunopathogenesis of multiple sclerosisMichael K RackeJournal of Neuroimmunology|July 26, 2016
Therapeutic developments for autoimmune demyelinating diseases: Musings from an MD (mouse doctor)Michael K RackeCurrent Opinion in Neurology|June 17, 2008
The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapiesMichael K RackeNature Reviews. Neurology|September 19, 2012
Disease mechanisms in MS: the potassium channel KIR4.1--a potential autoantigen in MSMichael K RackeJournal of Autoimmune Disorders|February 20, 2016
Analysis of miRNA in Normal Appearing White Matter to Identify Altered CNS Pathways in Multiple SclerosisMireia Guerau-de-Arellano, Yue Liu, Walter H Meisen, et al.Expert Opinion on Pharmacotherapy|May 26, 2009
Pharmacotherapy of multiple sclerosis: the PROOF trialAaron Boster, Michael K RackeExpert Review of Neurotherapeutics|March 11, 2009
Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?Erin E Longbrake, Michael K RackeCurrent Topics in Microbiology and Immunology|August 19, 2009
Toll-like receptors in multiple sclerosisMichael K Racke, Paul D DrewExpert Opinion on Therapeutic Targets|September 12, 2002
Targeting T cell costimulation in autoimmune diseaseRodney W Stuart, Michael K RackePageof 17